Figure 6

(a) Activated NK/NKT cells

Naive NK/NKT cells

Fcγ receptor

CD28

Dendritic cells

CD80/CD86

Ipilimumab

CTLA-4

(b) Naive T cells

Naive NK/NKT cells

OKT3

Ipilimumab

Activation/Proliferation

Suppressed CD4+ T cell Proliferation

Enhanced CD8+ T cell Proliferation

Persisting Activated NK/NKT cells

Tumor cells

Enhanced Cytotoxicity

IFN-γ

IL-10